BioCentury
ARTICLE | Financial News

Amgen climbs after CVOT readout

February 3, 2017 10:41 PM UTC

Amgen Inc. (NASDAQ:AMGN) rose $7.95 to $167.53 on Friday, adding about $5.9 billion in market cap, after the company said Repatha evolocumab met the primary endpoint in the Phase III FOURIER cardiovascular outcomes trial. Amgen reported the results Thursday after market hours, along with 4Q16 and full-year earnings (see BioCentury Extra, Feb. 2).

Repatha is the first PCSK9 inhibitor to show an effect on reducing CV risk when given on top of statins in a high-risk group of patients with dyslipidemia. Amgen did not provide details about the drug's margin of benefit. It plans to present detailed results from FOURIER on March 17 at the American College of Cardiology meeting in Washington, D.C...

BCIQ Target Profiles

PCSK9